#ASH18: Legend Biotech — allied with J&J now — continues to wow the crowd with their BCMA CAR-T update. What will bluebird say?
Back in the summer of 2017, an unknown Chinese biotech called Legend jumped into ASCO and disrupted the rep bluebird had carefully erected for itself as the breakaway leader among companies developing a BCMA-targeting CAR-T for multiple myeloma, offering up regular looks at one of the industry’s top development programs.
Legend offered startling proof-of-concept data to suggest that they could leapfrog the pack and land among the top companies pioneering the field. Soon after J&J followed up with a rich $350 million cash upfront to partner with Legend, offering their endorsement that the biotech was no fly-by-night pretender to the throne.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.